Krystal Biotech Inc expected to post a loss of 29 cents a share - Earnings Preview

Krystal Biotech

03/11/2023 15:57

* Krystal Biotech Inc  KRYS.OQ   KRYS.O  is expected to show
a
rise in quarterly revenue when it reports  results 
    * The Pittsburgh Pennsylvania-based  company is expected to
report
revenue of $6.321 million, according to the mean estimate from 7
analysts, based on LSEG data.  
    * ​Refinitiv's mean analyst estimate for Krystal Biotech Inc
is
for a loss of 29 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Krystal
Biotech
Inc is $153.5​, above​ its last closing price of $119.05. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.69       -0.74      -1.25     Missed  -69.7
 Mar. 31 2023  -1.43       -1.44      -1.76     Missed  -22.3
 Dec. 31 2022  -1.31       -1.32      -1.25     Beat    5.4​
 Sep. 30 2022  -1.23       -1.22      -1.17     Beat    3.9
 ​​Jun.        -0.99       -1.02      -1.10     Missed  -8.3
 30 2022                                                
 Mar. 31 2022  -1.06       -1.05      -0.99     Beat    5.6​
 Dec. 31 2021  -0.75       -0.73      -0.95     Missed  -29.7
 Sep. 30 2021  -0.76       -0.74      -0.70     Beat    5.2
 This summary was machine generated November 3 at 15:57 GMT.  All
figures in US dollars  unless otherwise stated